Results 11 to 20 of about 463,157 (302)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]

Endocrine Connections, 2018
Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe   +3 more
doaj   +5 more sources

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis

Chinese Medical Journal, 2017
Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj   +3 more sources

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 [PDF]

JAMA Oncology, 2019
Therapies to inhibit programmed cell death 1 and its ligand (anti-PD-1/PD-L1) provide significant survival benefits in many cancers, but the efficacy of these treatments varies considerably across different cancer types. Identifying the underlying variables associated with this cancer type-specific response remains an important open research challenge ...
Joo Sang, Lee, Eytan, Ruppin
openaire   +2 more sources

Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis. [PDF]

Case Rep Oncol
<b><i>Introduction:</i></b> The development of immune checkpoint inhibitors is considered one of the most important advances in cancer treatment. Pembrolizumab is an immune checkpoint inhibitor against programmed death-1 (PD-1) receptors that has demonstrated antineoplastic activity against various malignancies, including non ...
Tanimu Y, Coombs R, Tanimu S, Onitilo A.
europepmc   +4 more sources

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways. [PDF]

J Immunol
Abstract The advent of immune checkpoint blockade therapy has revolutionized cancer treatments and is partly responsible for the significant decline in cancer-related mortality observed during the last decade. Immune checkpoint inhibitors, such as anti–programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), have ...
Knutson KL.
europepmc   +3 more sources

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Polish Journal of Pathology, 2021
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan   +4 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma

Journal of Indian Academy of Oral Medicine and Radiology, 2023
Background: Programmed cell death-1 (PD-1) is expressed on the surface of activated T cells, while its ligand, PD-L1, is expressed on the surface of dendritic cells or macrophages. Objective: This study assessed the increased expression of PD-1 and PD-L1
Sonalika Srivastava, Abhishek Sinha, Sunita Srivastava, Anuj Mishra   +3 more
doaj   +1 more source

Targeting the programmed cell death-1 pathway in rheumatoid arthritis [PDF]

Autoimmunity Reviews, 2017
Since the introduction of TNF-α inhibitors and other biologic agents, the clinical outcome for many treated rheumatoid arthritis patients has significantly improved. However, there are still a substantial proportion of patients that are intolerant, or have inadequate responses, with current agents that have become the standards of care.
Sabina, Sandigursky, Gregg J, Silverman, Adam, Mor   +2 more
openaire   +2 more sources

Both the Caspase CSP-1 and a Caspase-Independent Pathway Promote Programmed Cell Death in Parallel to the Canonical Pathway for Apoptosis in Caenorhabditis elegans [PDF]

, 2012
Caspases are cysteine proteases that can drive apoptosis in metazoans and have critical functions in the elimination of cells during development, the maintenance of tissue homeostasis, and responses to cellular damage. Although a growing body of research
A Cauwels, A Degterev, A Gartner, A Raj, AH Wyllie, AM Chinnaiyan, B Conradt, B Pinan-Lucarre, B Schumacher, BT Hyman, D Xue, D Xue, Daniel P. Denning, DJ Dwyer, DJ Hoeppner, DP Denning, DT Harris, E Arama, E Pourkarimi, EC Andersen, EH Cheng, EM Hedgecock, ES Blum, F Chen, F Madeo, F Simmer, H. Robert Horvitz, HC Chang, Hermann Steller, HM Ellis, HT Schwartz, J Yuan, J Yuan, JE Sulston, JE Sulston, JF Kerr, JM Kinchen, JY Yuan, K Xu, M Darland-Ransom, MC Abraham, MC Abraham, MO Hengartner, MO Hengartner, NA Thornberry, PW Reddien, RA Lockshin, RE Ellis, S Brenner, S Harbinder, S Qi, S Seshagiri, S Shaham, S Shaham, S Shaham, SA Susin, T Hirose, TL Gumienny, V Venegas, VA Fadok, Victoria Hatch, X Geng, X Geng, X Wang, X Yang, Z Zhou   +65 more
core   +4 more sources